|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, CAR-T therapy-related severe cytokine release syndrome and neurological toxicity limit its clinical application in R/R DLBCL patients with high tumor burden.
|
31219975 |
2020 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report on the low incidence of severe cytokine release syndrome (CRS) in a subject treated with a CAR T-cell product composed of a defined ratio CD4:CD8 T-cell composition with a 4-1BB:zeta CAR targeting CD19 who also recieved early intervention treatment.
|
31697826 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
|
31428935 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
T cell-based therapies (blinatumomab and CAR T cell therapy) have produced unprecedented responses in relapsed and refractory (r/r) acute lymphoblastic leukemia (ALL) but is accompanied with significant toxicities, of which one of the most common and serious is cytokine release syndrome (CRS).
|
30666425 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, cytokine release syndrome in CAR-DLI group was manageable.
|
30829725 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The process of CAR-T cell transfusion was smooth, and there were no significant cytokine release syndrome manifestations after reinfusion.
|
31651858 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, CAR T-cell therapy is associated with multiple adverse effects, including neurotoxicity and cytokine release syndrome (CRS).
|
30804212 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, after CAR T cell infusion, 10 cases experienced a mild cytokine release syndrome (CRS), 6 had severe but manageable CRS, and 1 died of a very severe toxic reaction.
|
30988175 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) and CAR-T-associated encephalopathy syndrome (neurotoxicity) are the most common adverse effects associated with CAR-T therapy.
|
30560413 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Meanwhile, CAR-T therapy-related toxicities, including cytokine release syndrome (CRS) and neurological toxicities, are drawing researchers' attention.
|
31055613 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specific toxicities related to CAR-T like Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) could be fatal and need close monitoring and prompt treatment to avoid mortality and improve efficacy of the treatment.
|
31177852 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Areas covered</b>: CAR-T cell associated toxicities include cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES), alternatively known as immune effector cell-associated neurotoxicity syndrome (ICANS).
|
31219357 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokine release syndrome (CRS) remains to be a major adverse effect of chimeric antigen receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma.
|
30198955 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Management of cytokine release syndrome related to CAR-T cell therapy.
|
31571160 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The overwhelming release of cytokines and chemokines by activated CAR-T and other secondarily activated immune effector cells can lead to cytokine release syndrome (CRS), which can have clinical and pathophysiology similarities to systemic inflammatory response syndrome and macrophage activating syndrome/hemophagocytic lymphohistiocytosis.
|
31355491 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current research suggests that patients with a higher disease burden and higher CAR-T cell doses are positively associated with the development of ICANS, as are elevated serum levels of proinflammatory cytokines and the presence of cytokine release syndrome (CRS).
|
31327064 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most common severe adverse events in the CAR-T group were cytokine release syndrome, neurotoxicity and infection compared with cytopenia, gastrointestinal toxicity and infection in the ASCT group.
|
31335321 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the clinic, chimeric antigen receptor-modified T (CAR T) cell therapy is frequently associated with life-threatening cytokine-release syndrome (CRS) and neurotoxicity.
|
29808007 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nonetheless, the efficacy of CD19-specific CAR-T cell therapy can be offset by significant toxicities, such as cytokine release syndrome (CRS) and neurotoxicity.
|
29625831 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we review the wide spectrum of effects associated with CAR T cell therapy with a major focus on the pathogenesis of cytokine release syndrome and neurotoxicity as the most common, potentially life-threatening effects of this treatment.
|
30181581 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects.
|
30072559 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relevant challenges remain to be addressed, such as production time, early loss of CAR T cells, relapse due to loss of the target antigen, and prevention of severe cytokine release syndrome and neurotoxicity.
|
29171004 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Theoretically, CAR-NK cells have a more favorable toxicity profile compared to CAR T cells, especially in avoiding adverse effects such as cytokine release syndrome.
|
30034945 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
|
29895316 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) is the most significant complication associated with CAR T cell therapy, and it is critical to have a reproducible and easy method to grade CRS after CAR T cell infusions.
|
29499750 |
2018 |